1.2M XNYS Volume
XNYS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Sale of securities on an exchange or to another person at price $ 239.31 per share. | 10 Mar 2025 | 9,745 | 9,725 (0%) | 0% | 239.3 | 2,332,096 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 211.76 per share. | 10 Mar 2025 | 5,882 | 19,470 (0%) | 0% | 211.8 | 1,245,572 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. | 10 Mar 2025 | 3,589 | 13,588 (0%) | 0% | 146.3 | 525,214 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. | 10 Mar 2025 | 169 | 9,894 (0%) | 0% | 146.3 | 24,731 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 3,589 | 0 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,882 | 0 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 105 | 0 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 169 | 0 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 211.76 per share. | 10 Mar 2025 | 105 | 9,999 (0%) | 0% | 211.8 | 22,235 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 230.36 per share. | 10 Mar 2025 | 1,000 | 90,864 (0%) | 0% | 230.4 | 230,360 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 8,009 | 64,074 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 229.20 per share. | 07 Mar 2025 | 8,009 | 455,472 (0%) | 0% | 229.2 | 1,835,692 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. | 07 Mar 2025 | 8,009 | 463,481 (0%) | 0% | 101.6 | 814,035 | ResMed Common Stock |
| Peter C. Farrell | Director | Sale of securities on an exchange or to another person at price $ 227.71 per share. | 05 Mar 2025 | 2,000 | 75,218 (0%) | 0% | 227.7 | 455,420 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 4,726 | 5,882 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 211.76 per share. | 03 Mar 2025 | 367 | 10,092 (0%) | 0% | 211.8 | 77,716 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. | 03 Mar 2025 | 3,506 | 13,598 (0%) | 0% | 146.3 | 513,068 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. | 03 Mar 2025 | 514 | 14,112 (0%) | 0% | 146.3 | 75,219 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 211.76 per share. | 03 Mar 2025 | 4,726 | 18,838 (0%) | 0% | 211.8 | 1,000,778 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Sale of securities on an exchange or to another person at price $ 235.25 per share. | 03 Mar 2025 | 367 | 18,471 (0%) | 0% | 235.2 | 86,336 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Sale of securities on an exchange or to another person at price $ 235.40 per share. | 03 Mar 2025 | 3,506 | 14,965 (0%) | 0% | 235.4 | 825,308 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Sale of securities on an exchange or to another person at price $ 235.25 per share. | 03 Mar 2025 | 514 | 14,451 (0%) | 0% | 235.2 | 120,918 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Sale of securities on an exchange or to another person at price $ 235.43 per share. | 03 Mar 2025 | 4,726 | 9,725 (0%) | 0% | 235.4 | 1,112,624 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 367 | 105 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 3,506 | 3,589 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 514 | 169 | - | - | ResMed Common Stock Options | |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 234.09 per share. | 03 Mar 2025 | 64 | 8,910 (0%) | 0% | 234.1 | 14,982 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 238.98 per share. | 10 Feb 2025 | 1,000 | 91,864 (0%) | 0% | 239.0 | 238,980 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 236.77 per share. | 07 Feb 2025 | 8,009 | 455,472 (0%) | 0% | 236.8 | 1,896,307 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. | 07 Feb 2025 | 8,009 | 463,481 (0%) | 0% | 101.6 | 814,035 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 8,009 | 72,083 | - | - | ResMed Common Stock Options | |
| Peter C. Farrell | Director | Sale of securities on an exchange or to another person at price $ 242.11 per share. | 05 Feb 2025 | 2,000 | 77,218 (0%) | 0% | 242.1 | 484,220 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 242.42 per share. | 03 Feb 2025 | 64 | 8,974 (0%) | 0% | 242.4 | 15,515 | ResMed Common Stock |
| Peter C. Farrell | Director | Sale of securities on an exchange or to another person at price $ 230.99 per share. | 02 Jan 2025 | 2,000 | 79,218 (0%) | 0% | 231.0 | 461,980 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 230.99 per share. | 02 Jan 2025 | 75 | 9,038 (0%) | 0% | 231.0 | 17,324 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 244.23 per share. | 09 Dec 2024 | 1,000 | 93,864 (0%) | 0% | 244.2 | 244,230 | ResMed Common Stock |
| Peter C. Farrell | Director | Sale of securities on an exchange or to another person at price $ 245.65 per share. | 04 Dec 2024 | 2,000 | 81,218 (0%) | 0% | 245.7 | 491,300 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 248.91 per share. | 29 Nov 2024 | 74 | 9,113 (0%) | 0% | 248.9 | 18,419 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Nov 2024 | 173 | 9,187 (0%) | 0% | 0 | ResMed Common Stock | |
| Peter C. Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2024 | 1,468 | 1,468 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 249.66 per share. | 25 Nov 2024 | 2,000 | 0 (0%) | 0% | 249.7 | 499,330 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Nov 2024 | 2,000 | 2,090 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Nov 2024 | 2,000 | 2,000 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2024 | 33,036 | 33,036 | - | - | ResMed Common Stock Options | |
| Justin Leong | Chief Product Officer | Sale of securities on an exchange or to another person at price $ 243.09 per share. | 22 Nov 2024 | 6,160 | 21,718 (0%) | 0% | 243.1 | 1,497,416 | ReMed Common Stock |
| Peter C. Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 542 | 83,218 (0%) | 0% | 0 | ResMed Common Stock | |
| Ronald R. Taylor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 23,698 (0%) | 0% | 0 | ResMed Common Stock | |
| Richard Sulpizio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 17,796 (0%) | 0% | 0 | ResMed Common Stock | |
| Carol J. Burt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 2,851 (0%) | 0% | 0 | ResMed Common Stock | |
| Karen Drexler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 9,529 (0%) | 0% | 0 | ResMed Common Stock | |
| Harjit Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 9,905 (0%) | 0% | 0 | ResMed Common Stock | |
| Witte Jan De | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 7,806 (0%) | 0% | 0 | ReMed Common Stock | |
| Christopher DelOrefice | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 1,350 (0%) | 0% | 0 | ResMed Common Stock | |
| John Hernandez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 4,045 (0%) | 0% | 0 | ResMed Common Stock | |
| Desney Tan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 1,083 | 4,929 (0%) | 0% | 0 | ResMed Common Stock | |
| Witte Jan De | Director | Sale of securities on an exchange or to another person at price $ 248.81 per share. | 12 Nov 2024 | 796 | 6,723 (0%) | 0% | 248.8 | 198,053 | ReMed Common Stock |
| Peter C. Farrell | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.81 per share. | 11 Nov 2024 | 527 | 82,676 (0%) | 0% | 252.8 | 133,233 | ResMed Common Stock |
| Harjit Gill | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 253.53 per share. | 11 Nov 2024 | 132 | 8,822 (0%) | 0% | 253.5 | 33,466 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.54 per share. | 11 Nov 2024 | 1,417 | 9,725 (0%) | 0% | 252.5 | 357,856 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.71 per share. | 11 Nov 2024 | 445 | 11,142 (0%) | 0% | 252.7 | 112,457 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.41 per share. | 11 Nov 2024 | 603 | 11,588 (0%) | 0% | 252.4 | 152,204 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.74 per share. | 11 Nov 2024 | 684 | 9,803 (0%) | 0% | 252.7 | 172,875 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 253.93 per share. | 11 Nov 2024 | 136 | 9,360 (0%) | 0% | 253.9 | 34,535 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.84 per share. | 11 Nov 2024 | 172 | 9,497 (0%) | 0% | 252.8 | 43,488 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.95 per share. | 11 Nov 2024 | 134 | 9,669 (0%) | 0% | 252.9 | 33,895 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 249.00 per share. | 08 Nov 2024 | 1,000 | 94,864 (0%) | 0% | 249 | 249,000 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.41 per share. | 07 Nov 2024 | 3,101 | 461,152 (0%) | 0% | 252.4 | 782,725 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 246.26 per share. | 07 Nov 2024 | 14,683 | 464,254 (0%) | 0% | 246.3 | 3,615,821 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. | 07 Nov 2024 | 14,683 | 478,937 (0%) | 0% | 85.0 | 1,247,761 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 14,683 | 0 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.48 per share. | 07 Nov 2024 | 2,226 | 458,925 (0%) | 0% | 252.5 | 562,016 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.45 per share. | 07 Nov 2024 | 3,452 | 455,472 (0%) | 0% | 252.4 | 871,443 | ResMed Common Stock |
| Peter C. Farrell | Director | Sale of securities on an exchange or to another person at price $ 248.74 per share. | 06 Nov 2024 | 2,000 | 83,204 (0%) | 0% | 248.7 | 497,480 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 242.00 per share. | 01 Nov 2024 | 69 | 10,443 (0%) | 0% | 242 | 16,698 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Other type of transaction at price $ 0.00 per share. | 30 Oct 2024 | 9,628 | 9,628 (0%) | 0% | 0 | ResMed Common Stock | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Other type of transaction at price $ 0.00 per share. | 30 Oct 2024 | 9,628 | 12,160 (0%) | 0% | 0 | ResMed Common Stock | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 4,260 | 0 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Sale of securities on an exchange or to another person at price $ 238.48 per share. | 11 Oct 2024 | 4,260 | 21,788 (0%) | 0% | 238.5 | 1,015,925 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. | 11 Oct 2024 | 4,260 | 26,048 (0%) | 0% | 101.6 | 432,986 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 233.47 per share. | 08 Oct 2024 | 1,000 | 95,812 (0%) | 0% | 233.5 | 233,470 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 231.91 per share. | 07 Oct 2024 | 14,683 | 464,169 (0%) | 0% | 231.9 | 3,405,206 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. | 07 Oct 2024 | 14,683 | 478,852 (0%) | 0% | 85.0 | 1,247,761 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2024 | 14,683 | 14,683 | - | - | ResMed Common Stock Options | |
| Peter C. Farrell | Director | Sale of securities on an exchange or to another person at price $ 237.20 per share. | 02 Oct 2024 | 2,000 | 85,204 (0%) | 0% | 237.2 | 474,400 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2024 | 5,000 | 4,260 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Sale of securities on an exchange or to another person at price $ 252.56 per share. | 12 Sep 2024 | 5,000 | 21,788 (0%) | 0% | 252.6 | 1,262,800 | ResMed Common Stock |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. | 12 Sep 2024 | 5,000 | 26,788 (0%) | 0% | 101.6 | 508,200 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 246.42 per share. | 09 Sep 2024 | 1,000 | 96,812 (0%) | 0% | 246.4 | 246,420 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 248.38 per share. | 09 Sep 2024 | 14,683 | 464,169 (0%) | 0% | 248.4 | 3,646,950 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 14,683 | 29,366 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. | 09 Sep 2024 | 14,683 | 478,852 (0%) | 0% | 85.0 | 1,247,761 | ResMed Common Stock |
| Peter C. Farrell | Director | Sale of securities on an exchange or to another person at price $ 239.90 per share. | 04 Sep 2024 | 2,000 | 87,204 (0%) | 0% | 239.9 | 479,800 | ResMed Common Stock |
| Christopher DelOrefice | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 267 | 267 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 231.00 per share. | 20 Aug 2024 | 882 | 10,512 (0%) | 0% | 231 | 203,742 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 19,272 | 460,071 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 4,098 | 464,169 (0%) | 0% | 0 | ResMed Common Stock | |
| Brett A. Sandercock | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 841 | 97,812 (0%) | 0% | 0 | ResMed Common Stock | |
| Brett A. Sandercock | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 7,915 | 96,971 (0%) | 0% | 0 | ResMed Common Stock | |
| Justin Leong | Chief Product Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 878 | 27,878 (0%) | 0% | 0 | ReMed Common Stock | |
| Justin Leong | Chief Product Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 8,259 | 27,000 (0%) | 0% | 0 | ReMed Common Stock | |
| Kaushik Ghoshal | President, SaaS Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 841 | 21,788 (0%) | 0% | 0 | ResMed Common Stock | |
| Kaushik Ghoshal | President, SaaS Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 7,915 | 20,947 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Rider | Global General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 476 | 11,394 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Rider | Global General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 4,474 | 10,918 (0%) | 0% | 0 | ResMed Common Stock | |
| Kaushik Ghoshal | President, SaaS Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.80 per share. | 12 Aug 2024 | 2,086 | 15,118 (0%) | 0% | 95.8 | 199,839 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 1,037 | 9,260 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | President, SaaS Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 6,877 | 0 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | President, SaaS Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 2,086 | 0 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | President, SaaS Business | Sale of securities on an exchange or to another person at price $ 216.60 per share. | 12 Aug 2024 | 10,000 | 13,032 (0%) | 0% | 216.6 | 2,166,000 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. | 12 Aug 2024 | 1,037 | 23,032 (0%) | 0% | 101.6 | 105,401 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.80 per share. | 12 Aug 2024 | 6,877 | 21,995 (0%) | 0% | 95.8 | 658,817 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 212.16 per share. | 08 Aug 2024 | 1,000 | 89,056 (0%) | 0% | 212.2 | 212,160 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2024 | 14,683 | 44,049 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 214.25 per share. | 07 Aug 2024 | 14,683 | 440,799 (0%) | 0% | 214.3 | 3,145,905 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. | 07 Aug 2024 | 14,683 | 455,482 (0%) | 0% | 85.0 | 1,247,761 | ResMed Common Stock |
| Justin Leong | President, Asia Latin America | Sale of securities on an exchange or to another person at price $ 217.07 per share. | 05 Aug 2024 | 48,000 | 18,741 (0%) | 0% | 217.1 | 10,419,552 | ReMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 194.35 per share. | 08 Jul 2024 | 1,000 | 90,056 (0%) | 0% | 194.4 | 194,350 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2024 | 14,683 | 58,732 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 192.97 per share. | 08 Jul 2024 | 14,683 | 440,799 (0%) | 0% | 193.0 | 2,833,330 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. | 08 Jul 2024 | 14,683 | 455,482 (0%) | 0% | 85.0 | 1,247,761 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 209.81 per share. | 10 Jun 2024 | 1,000 | 91,056 (0%) | 0% | 209.8 | 209,810 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 14,683 | 73,415 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. | 07 Jun 2024 | 14,683 | 455,482 (0%) | 0% | 85.0 | 1,247,761 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 211.66 per share. | 07 Jun 2024 | 14,683 | 440,799 (0%) | 0% | 211.7 | 3,107,739 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 206.52 per share. | 04 Jun 2024 | 267 | 6,444 (0%) | 0% | 206.5 | 55,140 | ResMed Common Stock |
| Carol J. Burt | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 24 May 2024 | 47 | 14,892 (0%) | 0% | 0 | ResMed Common Stock | |
| Peter C. Farrell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 15 May 2024 | 68,200 | 89,204 (0%) | 0% | 0 | ResMed Common Stock | |
| Witte Jan De | Director | Sale of securities on an exchange or to another person at price $ 218.29 per share. | 15 May 2024 | 360 | 7,519 (0%) | 0% | 218.3 | 78,584 | ReMed Common Stock |
| Witte Jan De | Director | Sale of securities on an exchange or to another person at price $ 218.29 per share. | 15 May 2024 | 360 | 7,519 (0%) | 0% | 218.3 | 78,584 | ReMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. | 08 May 2024 | 12,000 | 105,056 (0%) | 0% | 101.6 | 1,219,680 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2024 | 12,000 | 10,883 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 211.37 per share. | 08 May 2024 | 13,000 | 92,056 (0%) | 0% | 211.4 | 2,747,810 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2024 | 13,507 | 88,098 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. | 07 May 2024 | 1,176 | 441,928 (0%) | 0% | 85.0 | 99,936 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.98 per share. | 07 May 2024 | 13,507 | 455,435 (0%) | 0% | 85.0 | 1,147,825 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 216.50 per share. | 07 May 2024 | 14,683 | 440,752 (0%) | 0% | 216.5 | 3,178,815 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2024 | 1,176 | 101,605 | - | - | ResMed Common Stock Options | |
| Karen Drexler | Director | Sale of securities on an exchange or to another person at price $ 214.92 per share. | 29 Apr 2024 | 425 | 8,446 (0%) | 0% | 214.9 | 91,341 | ResMed Common Stock |
| Carol J. Burt | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Apr 2024 | 234 | 14,939 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 180.00 per share. | 04 Mar 2024 | 81 | 6,607 (0%) | 0% | 180 | 14,580 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 173.25 per share. | 01 Mar 2024 | 200 | 6,688 (0%) | 0% | 173.3 | 34,650 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 152.62 per share. | 27 Nov 2023 | 3,000 | 92,962 (0%) | 0% | 152.6 | 457,860 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Nov 2023 | 72 | 6,888 (0%) | 0% | 0 | ResMed Common Stock | |
| Robert Andrew Douglas | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 148.96 per share. | 20 Nov 2023 | 1,375 | 13,849 (0%) | 0% | 149.0 | 204,825 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.34 per share. | 20 Nov 2023 | 366 | 12,908 (0%) | 0% | 149.3 | 54,657 | ResMed Common Stock |
| Peter C. Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 1,768 | 180,939 (0%) | 0% | 0 | ResMed Common Stock | |
| Ronald R. Taylor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 1,768 | 22,615 (0%) | 0% | 0 | ResMed Common Stock | |
| Richard Sulpizio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 1,768 | 16,713 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 148.90 per share. | 16 Nov 2023 | 1,343 | 443,105 (0%) | 0% | 148.9 | 199,973 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 16 Nov 2023 | 3,462 | 444,448 (0%) | 0% | 57.8 | 199,965 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.00 per share. | 16 Nov 2023 | 2,352 | 440,752 (0%) | 0% | 149.0 | 350,445 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2023 | 3,462 | 0 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 55,468 | 55,468 | - | - | ResMed Common Stock Options | |
| Carol J. Burt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 1,768 | 2,890 (0%) | 0% | 0 | ResMed Common Stock | |
| Karen Drexler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 884 | 8,871 (0%) | 0% | 0 | ResMed Common Stock | |
| Karen Drexler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 2,575 | 2,575 | - | - | ResMed Common Stock Options | |
| Harjit Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 1,768 | 8,955 (0%) | 0% | 0 | ResMed Common Stock | |
| Witte Jan De | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 1,768 | 7,879 (0%) | 0% | 0 | ReMed Common Stock | |
| John Hernandez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 884 | 2,962 (0%) | 0% | 0 | ResMed Common Stock | |
| John Hernandez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 2,575 | 2,575 | - | - | ResMed Common Stock Options | |
| Desney Tan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2023 | 1,768 | 3,846 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2023 | 5,678 | 3,462 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 152.04 per share. | 15 Nov 2023 | 5,678 | 440,986 (0%) | 0% | 152.0 | 863,281 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Nov 2023 | 5,678 | 446,664 (0%) | 0% | 57.8 | 327,961 | ResMed Common Stock |
| Peter C. Farrell | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.77 per share. | 13 Nov 2023 | 325 | 179,171 (0%) | 0% | 143.8 | 46,724 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.74 per share. | 13 Nov 2023 | 759 | 15,224 (0%) | 0% | 143.7 | 109,099 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.68 per share. | 13 Nov 2023 | 944 | 15,985 (0%) | 0% | 143.7 | 135,636 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.62 per share. | 13 Nov 2023 | 2,181 | 440,986 (0%) | 0% | 143.6 | 313,233 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.64 per share. | 13 Nov 2023 | 3,037 | 443,167 (0%) | 0% | 143.6 | 436,243 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.63 per share. | 13 Nov 2023 | 3,232 | 446,205 (0%) | 0% | 143.6 | 464,217 | ResMed Common Stock |
| Harjit Gill | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.96 per share. | 13 Nov 2023 | 79 | 7,187 (0%) | 0% | 144.0 | 11,373 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.78 per share. | 13 Nov 2023 | 590 | 13,711 (0%) | 0% | 143.8 | 84,829 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.91 per share. | 13 Nov 2023 | 435 | 13,275 (0%) | 0% | 143.9 | 62,601 | ResMed Common Stock |
| Lucile Blaise | President, Sleep & RC Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.98 per share. | 13 Nov 2023 | 135 | 10,305 (0%) | 0% | 144.0 | 19,437 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.60 per share. | 13 Nov 2023 | 91 | 7,308 (0%) | 0% | 144.6 | 13,159 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.17 per share. | 13 Nov 2023 | 93 | 6,960 (0%) | 0% | 144.2 | 13,408 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.23 per share. | 13 Nov 2023 | 136 | 7,054 (0%) | 0% | 144.2 | 19,615 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.30 per share. | 13 Nov 2023 | 117 | 7,190 (0%) | 0% | 144.3 | 16,883 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 143.44 per share. | 01 Nov 2023 | 25 | 7,358 (0%) | 0% | 143.4 | 3,586 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2023 | 5,675 | 9,140 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 140.70 per share. | 16 Oct 2023 | 5,675 | 449,360 (0%) | 0% | 140.7 | 798,464 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 16 Oct 2023 | 5,675 | 455,035 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 145.92 per share. | 02 Oct 2023 | 25 | 7,383 (0%) | 0% | 145.9 | 3,648 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2023 | 5,675 | 14,815 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 146.35 per share. | 15 Sep 2023 | 5,675 | 449,360 (0%) | 0% | 146.3 | 830,514 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Sep 2023 | 5,675 | 455,035 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 161.16 per share. | 01 Sep 2023 | 25 | 7,408 (0%) | 0% | 161.2 | 4,029 | ResMed Common Stock |
| Lucile Blaise | President, Sleep & RC Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 165.97 per share. | 25 Aug 2023 | 379 | 10,355 (0%) | 0% | 166.0 | 62,903 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 4,972 | 95,915 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 12,430 | 449,360 (0%) | 0% | 0 | ResMed Common Stock | |
| Kaushik Ghoshal | President, SaaS Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 2,486 | 14,273 (0%) | 0% | 0 | ResMed Common Stock | |
| Lucile Blaise | President, Sleep & RC Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 819 | 7,441 (0%) | 0% | 0 | ResMed Common Stock | |
| Lucile Blaise | President, Sleep & RC Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 3,294 | 10,735 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Rider | Global General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2023 | 2,247 | 7,433 (0%) | 0% | 0 | ResMed Common Stock | |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 181.01 per share. | 15 Aug 2023 | 1,500 | 250,526 (0%) | 0% | 181.0 | 271,515 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 5,675 | 20,490 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 183.20 per share. | 15 Aug 2023 | 5,675 | 436,930 (0%) | 0% | 183.2 | 1,039,647 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Aug 2023 | 5,675 | 442,605 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 224.12 per share. | 01 Aug 2023 | 25 | 5,186 (0%) | 0% | 224.1 | 5,603 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 222.22 per share. | 17 Jul 2023 | 1,500 | 252,026 (0%) | 0% | 222.2 | 333,330 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 5,675 | 26,165 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 221.27 per share. | 17 Jul 2023 | 5,675 | 436,930 (0%) | 0% | 221.3 | 1,255,686 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 17 Jul 2023 | 5,675 | 442,605 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Sale of securities on an exchange or to another person at price $ 220.00 per share. | 13 Jul 2023 | 500 | 11,787 (0%) | 0% | 220 | 110,000 | ResMed Common Stock |
| Michael J. Rider | Global General Counsel | Sale of securities on an exchange or to another person at price $ 217.20 per share. | 03 Jul 2023 | 25 | 5,211 (0%) | 0% | 217.2 | 5,430 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 216.27 per share. | 15 Jun 2023 | 1,500 | 253,526 (0%) | 0% | 216.3 | 324,405 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 217.39 per share. | 15 Jun 2023 | 5,675 | 436,930 (0%) | 0% | 217.4 | 1,233,716 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 5,675 | 31,840 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Jun 2023 | 5,675 | 442,605 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 219.79 per share. | 05 Jun 2023 | 1,500 | 89,729 (0%) | 0% | 219.8 | 329,685 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Sale of securities on an exchange or to another person at price $ 220.00 per share. | 02 Jun 2023 | 500 | 12,287 (0%) | 0% | 220 | 110,000 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 232.85 per share. | 15 May 2023 | 1,500 | 255,026 (0%) | 0% | 232.9 | 349,275 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 5,675 | 37,515 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 232.10 per share. | 15 May 2023 | 5,675 | 436,930 (0%) | 0% | 232.1 | 1,317,191 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 May 2023 | 5,675 | 442,605 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 233.13 per share. | 10 May 2023 | 12,574 | 90,942 (0%) | 0% | 233.1 | 2,931,395 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 232.05 per share. | 09 May 2023 | 3,426 | 103,516 (0%) | 0% | 232.0 | 795,000 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 237.64 per share. | 03 May 2023 | 1,500 | 91,172 (0%) | 0% | 237.6 | 356,460 | ResMed Common Stock |
| Peter Farrell C. | Director | Sale of securities on an exchange or to another person at price $ 182.66 per share. | 03 May 2023 | 10,935 | 157,404 (0%) | 0% | 182.7 | 1,997,434 | ResMed Common Stock |
| C. Peter Farrell | Director | Sale of securities on an exchange or to another person at price $ 237.17 per share. | 03 May 2023 | 12,600 | 166,896 (0%) | 0% | 237.2 | 2,988,375 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Sale of securities on an exchange or to another person at price $ 239.30 per share. | 01 May 2023 | 500 | 12,704 (0%) | 0% | 239.3 | 119,650 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Sale of securities on an exchange or to another person at price $ 230.00 per share. | 24 Apr 2023 | 2,000 | 13,204 (0%) | 0% | 230 | 460,000 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 224.65 per share. | 17 Apr 2023 | 1,500 | 256,526 (0%) | 0% | 224.7 | 336,975 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 5,675 | 43,190 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 224.23 per share. | 17 Apr 2023 | 5,675 | 436,900 (0%) | 0% | 224.2 | 1,272,526 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 17 Apr 2023 | 5,675 | 442,575 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 218.23 per share. | 03 Apr 2023 | 1,500 | 92,672 (0%) | 0% | 218.2 | 327,345 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Sale of securities on an exchange or to another person at price $ 220.00 per share. | 03 Apr 2023 | 500 | 15,204 (0%) | 0% | 220 | 110,000 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 206.14 per share. | 15 Mar 2023 | 1,500 | 258,026 (0%) | 0% | 206.1 | 309,210 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Mar 2023 | 1,919 | 259,526 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 206.95 per share. | 15 Mar 2023 | 5,675 | 436,900 (0%) | 0% | 207.0 | 1,174,451 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Mar 2023 | 5,675 | 442,575 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 5,675 | 48,865 | - | - | ResMed Common Stock Options | |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 216.69 per share. | 03 Mar 2023 | 1,500 | 94,172 (0%) | 0% | 216.7 | 325,035 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Sale of securities on an exchange or to another person at price $ 220.00 per share. | 03 Mar 2023 | 1,000 | 15,704 (0%) | 0% | 220 | 220,000 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 215.22 per share. | 17 Feb 2023 | 10,000 | 106,880 (0%) | 0% | 215.2 | 2,152,196 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 213.50 per share. | 15 Feb 2023 | 1,500 | 261,445 (0%) | 0% | 213.5 | 320,250 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Feb 2023 | 5,675 | 442,575 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 214.83 per share. | 15 Feb 2023 | 5,675 | 436,900 (0%) | 0% | 214.8 | 1,219,144 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 5,675 | 54,540 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 215.00 per share. | 13 Feb 2023 | 4,000 | 116,880 (0%) | 0% | 215 | 860,000 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 224.50 per share. | 03 Feb 2023 | 1,500 | 95,672 (0%) | 0% | 224.5 | 336,750 | ResMed Common Stock |
| Karen Drexler | Director | Sale of securities on an exchange or to another person at price $ 226.58 per share. | 02 Feb 2023 | 594 | 7,987 (0%) | 0% | 226.6 | 134,589 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 220.43 per share. | 17 Jan 2023 | 1,500 | 226,208 (0%) | 0% | 220.4 | 330,645 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 5,675 | 60,215 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 17 Jan 2023 | 5,675 | 442,575 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 224.36 per share. | 17 Jan 2023 | 5,675 | 436,900 (0%) | 0% | 224.4 | 1,273,269 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 210.07 per share. | 03 Jan 2023 | 1,500 | 97,172 (0%) | 0% | 210.1 | 315,105 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2022 | 5,675 | 65,890 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 215.63 per share. | 15 Dec 2022 | 5,675 | 436,900 (0%) | 0% | 215.6 | 1,223,727 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Dec 2022 | 5,675 | 442,575 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 229.81 per share. | 05 Dec 2022 | 1,500 | 98,672 (0%) | 0% | 229.8 | 344,715 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Nov 2022 | 7,300 | 100,172 (0%) | 0% | 0 | ResMed Common Stock | |
| David B. Pendarvis | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 683 | 12,540 | - | - | ResMed Common Stock Options | |
| David B. Pendarvis | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.34 per share. | 25 Nov 2022 | 683 | 107,472 (0%) | 0% | 146.3 | 99,950 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. | 23 Nov 2022 | 19,425 | 53,556 (0%) | 0% | 224.4 | 4,358,970 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 32,795 | 72,981 (0%) | 0% | 0 | ResMed Common Stock | |
| Brett A. Sandercock | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 14,577 | 120,880 (0%) | 0% | 0 | ResMed Common Stock | |
| David B. Pendarvis | Chief Administrative Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 12,389 | 113,700 (0%) | 0% | 0 | ResMed Common Stock | |
| David B. Pendarvis | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. | 23 Nov 2022 | 6,911 | 106,789 (0%) | 0% | 224.4 | 1,550,828 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. | 23 Nov 2022 | 33,239 | 436,900 (0%) | 0% | 224.4 | 7,458,832 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 56,115 | 470,139 (0%) | 0% | 0 | ResMed Common Stock | |
| Kaushik Ghoshal | President, SaaS Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. | 23 Nov 2022 | 4,318 | 16,704 (0%) | 0% | 224.4 | 968,959 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 7,288 | 21,022 (0%) | 0% | 0 | ResMed Common Stock | |
| Justin Leong | President, Asia Latin America | Sale of securities on an exchange or to another person at price $ 229.50 per share. | 22 Nov 2022 | 3,777 | 59,817 (0%) | 0% | 229.5 | 866,820 | ReMed Common Stock |
| Justin Leong | President, Asia Latin America | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2022 | 15,000 | 0 | - | - | ResMed Common Stock Options | |
| Justin Leong | President, Asia Latin America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2022 | 6,924 | 66,741 (0%) | 0% | 0 | ReMed Common Stock | |
| Justin Leong | President, Asia Latin America | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 22 Nov 2022 | 15,000 | 63,594 (0%) | 0% | 57.8 | 866,400 | ReMed Common Stock |
| Lucile Blaise | President, Sleep & RC Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. | 21 Nov 2022 | 78 | 6,627 (0%) | 0% | 224.4 | 17,503 | ResMed Common Stock |
| Lucile Blaise | President, Sleep & RC Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. | 21 Nov 2022 | 75 | 6,552 (0%) | 0% | 224.4 | 16,830 | ResMed Common Stock |
| Lucile Blaise | President, Sleep & RC Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.40 per share. | 21 Nov 2022 | 114 | 6,705 (0%) | 0% | 224.4 | 25,582 | ResMed Common Stock |
| Richard Sulpizio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2022 | 1,122 | 14,945 (0%) | 0% | 0 | ResMed Common Stock | |
| Peter C. Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 1,122 | 179,496 (0%) | 0% | 0 | ResMed Common Stock | |
| Ronald R. Taylor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 1,122 | 20,847 (0%) | 0% | 0 | ResMed Common Stock | |
| Carol J. Burt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 1,122 | 2,078 (0%) | 0% | 0 | ResMed Common Stock | |
| Karen Drexler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 1,122 | 8,581 (0%) | 0% | 0 | ResMed Common Stock | |
| Harjit Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 1,122 | 7,266 (0%) | 0% | 0 | ResMed Common Stock | |
| Witte Jan De | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 1,122 | 6,111 (0%) | 0% | 0 | ReMed Common Stock | |
| Robert Andrew Douglas | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 31,649 | 31,649 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 36,569 | 36,569 | - | - | ResMed Common Stock Options | |
| Justin Leong | President, Asia Latin America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 9,973 | 9,973 | - | - | ResMed Common Stock Options | |
| Kaushik Ghoshal | President, SaaS Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 7,314 | 7,314 | - | - | ResMed Common Stock Options | |
| John Hernandez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 1,122 | 2,078 (0%) | 0% | 0 | ResMed Common Stock | |
| Desney Tan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2022 | 1,122 | 2,078 (0%) | 0% | 0 | ResMed Common Stock | |
| Lucile Blaise | President, Sleep & RC Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2022 | 2,410 | 2,410 | - | - | ResMed Common Stock Options | |
| Lucile Blaise | President, Sleep & RC Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 15 Nov 2022 | 169 | 6,819 (0%) | 0% | 225.2 | 38,055 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 222.07 per share. | 15 Nov 2022 | 11,280 | 40,186 (0%) | 0% | 222.1 | 2,504,939 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2022 | 16,888 | 0 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2022 | 1,144 | 16,888 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 15 Nov 2022 | 16,888 | 51,466 (0%) | 0% | 58.2 | 983,557 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 15 Nov 2022 | 1,144 | 34,578 (0%) | 0% | 58.2 | 66,627 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2022 | 5,675 | 71,565 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Nov 2022 | 5,675 | 419,699 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 224.64 per share. | 15 Nov 2022 | 5,675 | 414,024 (0%) | 0% | 224.6 | 1,274,837 | ResMed Common Stock |
| Lucile Blaise | President, Sleep & RC Business | Sale of securities on an exchange or to another person at price $ 225.18 per share. | 15 Nov 2022 | 169 | 7,335 (0%) | 0% | 225.2 | 38,055 | ResMed Common Stock |
| Lucile Blaise | President, Sleep & RC Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 225.18 per share. | 15 Nov 2022 | 516 | 7,504 (0%) | 0% | 225.2 | 116,193 | ResMed Common Stock |
| Peter C. Farrell | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 128 | 178,374 (0%) | 0% | 225.2 | 28,823 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 760 | 33,434 (0%) | 0% | 225.2 | 171,137 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 945 | 34,194 (0%) | 0% | 225.2 | 212,795 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 450 | 101,927 (0%) | 0% | 225.2 | 101,331 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 279 | 101,311 (0%) | 0% | 225.2 | 62,825 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 337 | 101,590 (0%) | 0% | 225.2 | 75,886 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 3,038 | 414,024 (0%) | 0% | 225.2 | 684,097 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 3,233 | 417,062 (0%) | 0% | 225.2 | 728,007 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 2,359 | 420,295 (0%) | 0% | 225.2 | 531,200 | ResMed Common Stock |
| Harjit Gill | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.17 per share. | 11 Nov 2022 | 41 | 6,144 (0%) | 0% | 225.2 | 9,232 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 307 | 14,325 (0%) | 0% | 225.2 | 69,130 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 225.18 per share. | 11 Nov 2022 | 591 | 13,734 (0%) | 0% | 225.2 | 133,081 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Nov 2022 | 1,000 | 4,090 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 220.83 per share. | 10 Nov 2022 | 4,880 | 0 (0%) | 0% | 220.8 | 1,077,650 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Nov 2022 | 1,000 | 4,880 (0%) | 0% | 0 | ResMed Common Stock | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 212.02 per share. | 07 Nov 2022 | 4,000 | 106,303 (0%) | 0% | 212.0 | 848,068 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 215.23 per share. | 03 Nov 2022 | 1,545 | 102,334 (0%) | 0% | 215.2 | 332,530 | ResMed Common Stock |
| Peter C. Farrell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Oct 2022 | 4,550 | 178,502 (0%) | 0% | 0 | ResMed Common Stock | |
| Peter C. Farrell | Director | Sale of securities on an exchange or to another person at price $ 221.98 per share. | 31 Oct 2022 | 9,050 | 183,052 (0%) | 0% | 222.0 | 2,008,877 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 17 Oct 2022 | 5,675 | 428,245 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 214.58 per share. | 17 Oct 2022 | 5,675 | 422,570 (0%) | 0% | 214.6 | 1,217,723 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 5,675 | 77,240 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 14 Oct 2022 | 1,145 | 29,553 (0%) | 0% | 58.2 | 66,685 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2022 | 16,888 | 18,032 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2022 | 1,145 | 34,920 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 215.09 per share. | 14 Oct 2022 | 11,355 | 35,086 (0%) | 0% | 215.1 | 2,442,298 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 14 Oct 2022 | 16,888 | 46,441 (0%) | 0% | 58.2 | 983,557 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 220.19 per share. | 03 Oct 2022 | 1,545 | 103,879 (0%) | 0% | 220.2 | 340,194 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Sep 2022 | 5,675 | 428,245 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 5,675 | 82,915 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 228.96 per share. | 15 Sep 2022 | 5,675 | 422,570 (0%) | 0% | 229.0 | 1,299,336 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Sep 2022 | 1,287 | 227,708 (0%) | 0% | 0 | ResMed Common Stock | |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 16,888 | 36,065 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 1,145 | 52,953 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 15 Sep 2022 | 16,888 | 39,597 (0%) | 0% | 58.2 | 983,557 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 15 Sep 2022 | 1,145 | 22,709 (0%) | 0% | 58.2 | 66,685 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 232.38 per share. | 15 Sep 2022 | 6,000 | 228,995 (0%) | 0% | 232.4 | 1,394,280 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 232.51 per share. | 15 Sep 2022 | 11,189 | 28,408 (0%) | 0% | 232.5 | 2,601,583 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 216.92 per share. | 06 Sep 2022 | 1,545 | 105,424 (0%) | 0% | 216.9 | 335,141 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2022 | 4,328 | 21,564 (0%) | 0% | 0 | ResMed Common Stock | |
| Brett A. Sandercock | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2022 | 3,847 | 110,273 (0%) | 0% | 0 | ResMed Common Stock | |
| David B. Pendarvis | Chief Administrative Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2022 | 1,683 | 106,969 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2022 | 17,310 | 422,570 (0%) | 0% | 0 | ResMed Common Stock | |
| Kaushik Ghoshal | President, SaaS Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2022 | 3,366 | 14,628 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 238.09 per share. | 15 Aug 2022 | 5,675 | 405,260 (0%) | 0% | 238.1 | 1,351,166 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Aug 2022 | 5,675 | 410,935 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2022 | 5,675 | 88,590 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 240.66 per share. | 10 Aug 2022 | 2,500 | 106,426 (0%) | 0% | 240.7 | 601,650 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 10 Aug 2022 | 2,500 | 108,926 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2022 | 2,500 | 0 | - | - | ResMed Common Stock Options | |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 240.72 per share. | 03 Aug 2022 | 1,545 | 105,286 (0%) | 0% | 240.7 | 371,912 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 22 Jul 2022 | 2,500 | 113,926 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 22 Jul 2022 | 2,500 | 108,926 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2022 | 2,500 | 2,500 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2022 | 2,500 | 5,000 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2022 | 2,500 | 7,500 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 235.00 per share. | 22 Jul 2022 | 7,500 | 106,426 (0%) | 0% | 235 | 1,762,500 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 22 Jul 2022 | 2,500 | 111,426 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Jul 2022 | 5,675 | 410,935 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 5,675 | 94,265 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 224.94 per share. | 15 Jul 2022 | 5,675 | 405,260 (0%) | 0% | 224.9 | 1,276,517 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 212.33 per share. | 05 Jul 2022 | 1,545 | 106,831 (0%) | 0% | 212.3 | 328,050 | ResMed Common Stock |
| Richard Sulpizio | Director | 30 Jun 2022 | 956 | 13,823 (0%) | 0% | 0 | ResMed Common Stock | ||
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Jun 2022 | 5,675 | 410,935 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 5,675 | 99,940 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 202.54 per share. | 15 Jun 2022 | 5,675 | 405,260 (0%) | 0% | 202.5 | 1,149,410 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 209.44 per share. | 03 Jun 2022 | 1,545 | 108,376 (0%) | 0% | 209.4 | 323,585 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 16 May 2022 | 5,675 | 410,935 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 5,675 | 105,615 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 196.61 per share. | 16 May 2022 | 5,675 | 405,260 (0%) | 0% | 196.6 | 1,115,745 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 200.00 per share. | 03 May 2022 | 1,545 | 109,858 (0%) | 0% | 200 | 309,000 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2022 | 8,000 | 54,098 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 233.29 per share. | 18 Apr 2022 | 8,000 | 17,175 (0%) | 0% | 233.3 | 1,866,320 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 18 Apr 2022 | 8,000 | 25,175 (0%) | 0% | 58.2 | 465,920 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 232.41 per share. | 18 Apr 2022 | 5,675 | 405,229 (0%) | 0% | 232.4 | 1,318,947 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 18 Apr 2022 | 5,675 | 410,904 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2022 | 5,675 | 111,290 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 11 Apr 2022 | 2,500 | 108,854 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2022 | 2,500 | 10,000 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 247.00 per share. | 11 Apr 2022 | 2,500 | 106,354 (0%) | 0% | 247 | 617,500 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 246.60 per share. | 04 Apr 2022 | 1,544 | 111,403 (0%) | 0% | 246.6 | 380,750 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 238.07 per share. | 15 Mar 2022 | 8,000 | 17,175 (0%) | 0% | 238.1 | 1,904,560 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 8,000 | 62,098 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 15 Mar 2022 | 8,000 | 25,175 (0%) | 0% | 58.2 | 465,920 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 242.37 per share. | 15 Mar 2022 | 5,675 | 405,229 (0%) | 0% | 242.4 | 1,375,422 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Mar 2022 | 5,675 | 410,904 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 5,675 | 116,965 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 10 Mar 2022 | 2,500 | 108,854 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,500 | 12,500 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 241.29 per share. | 10 Mar 2022 | 2,500 | 106,354 (0%) | 0% | 241.3 | 603,225 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 250.62 per share. | 03 Mar 2022 | 1,544 | 112,947 (0%) | 0% | 250.6 | 386,957 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2022 | 8,000 | 70,098 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 235.81 per share. | 15 Feb 2022 | 8,000 | 17,175 (0%) | 0% | 235.8 | 1,886,480 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 15 Feb 2022 | 8,000 | 25,175 (0%) | 0% | 58.2 | 465,920 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 234.06 per share. | 15 Feb 2022 | 5,675 | 405,229 (0%) | 0% | 234.1 | 1,328,271 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Feb 2022 | 5,675 | 410,904 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2022 | 5,675 | 122,640 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 10 Feb 2022 | 2,500 | 108,854 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 2,500 | 15,000 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 241.86 per share. | 10 Feb 2022 | 2,500 | 106,354 (0%) | 0% | 241.9 | 604,650 | ResMed Common Stock |
| David B. Pendarvis | Chief Administration Officer | Sale of securities on an exchange or to another person at price $ 232.87 per share. | 03 Feb 2022 | 1,544 | 114,491 (0%) | 0% | 232.9 | 359,551 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 18 Jan 2022 | 8,000 | 25,175 (0%) | 0% | 58.2 | 465,920 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 8,000 | 78,098 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 247.80 per share. | 18 Jan 2022 | 8,000 | 17,175 (0%) | 0% | 247.8 | 1,982,400 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 241.94 per share. | 18 Jan 2022 | 5,675 | 405,229 (0%) | 0% | 241.9 | 1,372,991 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 5,675 | 128,315 | - | - | ResMed Common Stock Options | |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 18 Jan 2022 | 5,675 | 410,904 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2022 | 2,500 | 17,500 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 10 Jan 2022 | 2,500 | 108,854 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 235.00 per share. | 10 Jan 2022 | 2,500 | 106,354 (0%) | 0% | 235 | 587,500 | ResMed Common Stock |
| David B. Pendarvis | Chief Administration Officer | Sale of securities on an exchange or to another person at price $ 258.52 per share. | 03 Jan 2022 | 1,544 | 116,035 (0%) | 0% | 258.5 | 399,155 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 15 Dec 2021 | 8,000 | 25,175 (0%) | 0% | 58.2 | 465,920 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2021 | 8,000 | 86,098 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO | Sale of securities on an exchange or to another person at price $ 256.52 per share. | 15 Dec 2021 | 8,000 | 17,175 (0%) | 0% | 256.5 | 2,052,160 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 255.53 per share. | 15 Dec 2021 | 5,675 | 405,229 (0%) | 0% | 255.5 | 1,450,141 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 15 Dec 2021 | 5,675 | 410,904 (0%) | 0% | 57.8 | 327,788 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2021 | 5,675 | 133,990 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 10 Dec 2021 | 2,500 | 108,854 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 2,500 | 20,000 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 264.92 per share. | 10 Dec 2021 | 2,500 | 106,354 (0%) | 0% | 264.9 | 662,300 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 257.93 per share. | 03 Dec 2021 | 1,544 | 117,579 (0%) | 0% | 257.9 | 398,244 | ResMed Common Stock |
| James R. Hollingshead | President, Sleep Business | Sale of securities on an exchange or to another person at price $ 256.84 per share. | 01 Dec 2021 | 2,400 | 76,721 (0%) | 0% | 256.8 | 616,416 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Nov 2021 | 3,880 | 3,880 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Nov 2021 | 3,880 | 5,090 (0%) | 0% | 0 | ResMed Common Stock | |
| Justin Leong | President, Asia Latin America | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.81 per share. | 24 Nov 2021 | 1,339 | 48,391 (0%) | 0% | 254.8 | 341,191 | ReMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Nov 2021 | 791 | 234,995 (0%) | 0% | 0 | ResMed Common Stock | |
| Carol J. Burt | Director | Sale of securities on an exchange or to another person at price $ 260.00 per share. | 22 Nov 2021 | 1,500 | 13,095 (0%) | 0% | 260 | 390,000 | ResMed Common Stock |
| Peter C. Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 1,695 | 1,695 | - | - | ResMed Common Stock Options | |
| Peter C. Farrell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 478 | 192,102 (0%) | 0% | 0 | ResMed Common Stock | |
| Robert Andrew Douglas | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 15,252 | 15,252 | - | - | ResMed Common Stock Options | |
| Ronald R. Taylor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 956 | 19,725 (0%) | 0% | 0 | ResMed Common Stock | |
| David B. Pendarvis | Chief Administration Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 5,931 | 5,931 | - | - | ResMed Common Stock Options | |
| Carol J. Burt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 956 | 15,551 (0%) | 0% | 0 | ResMed Common Stock | |
| Carol J. Burt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 956 | 14,595 (0%) | 0% | 0 | ResMed Common Stock | |
| Karen Drexler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 478 | 7,459 (0%) | 0% | 0 | ResMed Common Stock | |
| Karen Drexler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 1,695 | 1,695 | - | - | ResMed Common Stock Options | |
| Harjit Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 956 | 6,185 (0%) | 0% | 0 | ResMed Common Stock | |
| Witte Jan De | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 956 | 4,989 (0%) | 0% | 0 | ResMed Common Stock | |
| Justin Leong | President, Asia and LATAM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2021 | 8,134 | 8,134 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO ResMed Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.81 per share. | 16 Nov 2021 | 27,135 | 39,942 (0%) | 0% | 254.8 | 6,914,269 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 2,612 | 42,554 (0%) | 0% | 0 | ResMed Common Stock | |
| Robert Andrew Douglas | President and COO ResMed Inc. | Grant, award, or other acquisition of securities at price $ 254.81 per share. | 16 Nov 2021 | 45,811 | 67,077 (0%) | 0% | 254.8 | 11,673,101 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 1,161 | 106,354 (0%) | 0% | 0 | ResMed Common Stock | |
| Brett A. Sandercock | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 254.81 per share. | 16 Nov 2021 | 20,360 | 105,193 (0%) | 0% | 254.8 | 5,187,932 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Grant, award, or other acquisition of securities at price $ 254.81 per share. | 16 Nov 2021 | 17,307 | 127,792 (0%) | 0% | 254.8 | 4,409,997 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 986 | 119,123 (0%) | 0% | 0 | ResMed Common Stock | |
| David B. Pendarvis | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.81 per share. | 16 Nov 2021 | 9,655 | 118,137 (0%) | 0% | 254.8 | 2,460,191 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Nov 2021 | 44,250 | 405,229 (0%) | 0% | 0 | ResMed Common Stock | |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 254.81 per share. | 16 Nov 2021 | 71,262 | 487,220 (0%) | 0% | 254.8 | 18,158,270 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.81 per share. | 16 Nov 2021 | 42,210 | 445,010 (0%) | 0% | 254.8 | 10,755,530 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 4,469 | 449,479 (0%) | 0% | 0 | ResMed Common Stock | |
| James R. Hollingshead | President, Sleep Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.81 per share. | 16 Nov 2021 | 12,060 | 77,412 (0%) | 0% | 254.8 | 3,073,009 | ResMed Common Stock |
| James R. Hollingshead | President, Sleep Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 316 | 79,121 (0%) | 0% | 0 | ResMed Common Stock | |
| James R. Hollingshead | President, Sleep Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 1,393 | 78,805 (0%) | 0% | 0 | ResMed Common Stock | |
| James R. Hollingshead | President, Sleep Business | Grant, award, or other acquisition of securities at price $ 254.81 per share. | 16 Nov 2021 | 20,360 | 89,472 (0%) | 0% | 254.8 | 5,187,932 | ResMed Common Stock |
| Justin Leong | President, Asia Latin America | Grant, award, or other acquisition of securities at price $ 254.81 per share. | 16 Nov 2021 | 9,162 | 49,857 (0%) | 0% | 254.8 | 2,334,569 | ReMed Common Stock |
| Justin Leong | President, Asia Latin America | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.81 per share. | 16 Nov 2021 | 765 | 49,092 (0%) | 0% | 254.8 | 194,930 | ReMed Common Stock |
| Justin Leong | President, Asia Latin America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 638 | 49,730 (0%) | 0% | 0 | ReMed Common Stock | |
| Kaushik Ghoshal | President, SaaS Business | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 697 | 11,171 (0%) | 0% | 0 | ResMed Common Stock | |
| Kaushik Ghoshal | President, SaaS Business | Grant, award, or other acquisition of securities at price $ 254.81 per share. | 16 Nov 2021 | 9,162 | 15,586 (0%) | 0% | 254.8 | 2,334,569 | ResMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.81 per share. | 16 Nov 2021 | 5,112 | 10,474 (0%) | 0% | 254.8 | 1,302,589 | ResMed Common Stock |
| Justin Leong | President, Asia Latin America | Payment of exercise price or tax liability using portion of securities received from the company at price $ 259.47 per share. | 16 Nov 2021 | 562 | 49,295 (0%) | 0% | 259.5 | 145,822 | ReMed Common Stock |
| Justin Leong | President, Asia Latin America | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2021 | 638 | 49,933 (0%) | 0% | 0 | ReMed Common Stock | |
| Justin Leong | President, Asia Latin America | Grant, award, or other acquisition of securities at price $ 254.81 per share. | 16 Nov 2021 | 9,162 | 49,857 (0%) | 0% | 254.8 | 2,334,569 | ReMed Common Stock |
| Carol J. Burt | Director | Sale of securities on an exchange or to another person at price $ 270.80 per share. | 15 Nov 2021 | 1,187 | 0 (0%) | 0% | 270.8 | 321,440 | ResMed Common Stock |
| Peter C. Farrell | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 259.47 per share. | 11 Nov 2021 | 342 | 191,624 (0%) | 0% | 259.5 | 88,739 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 8,000 | 94,098 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO ResMed Inc. | Sale of securities on an exchange or to another person at price $ 271.75 per share. | 11 Nov 2021 | 8,000 | 21,266 (0%) | 0% | 271.8 | 2,174,000 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 11 Nov 2021 | 8,000 | 29,266 (0%) | 0% | 58.2 | 465,920 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 259.47 per share. | 11 Nov 2021 | 945 | 21,266 (0%) | 0% | 259.5 | 245,199 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 983 | 18,468 | - | - | ResMed Common Stock Options | |
| David B. Pendarvis | Chief Administrative Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2021 | 10,000 | 110,485 (0%) | 0% | 0 | ResMed Common Stock | |
| David B. Pendarvis | Chief Administrative Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.64 per share. | 11 Nov 2021 | 983 | 120,485 (0%) | 0% | 101.6 | 99,912 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 259.47 per share. | 11 Nov 2021 | 1,549 | 119,502 (0%) | 0% | 259.5 | 401,919 | ResMed Common Stock |
| Michael J. Farrell | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 259.47 per share. | 11 Nov 2021 | 8,748 | 415,958 (0%) | 0% | 259.5 | 2,269,844 | ResMed Common Stock |
| James R. Hollingshead | President, Sleep Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 259.47 per share. | 11 Nov 2021 | 4,100 | 69,112 (0%) | 0% | 259.5 | 1,063,827 | ResMed Common Stock |
| Witte Jan De | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 259.47 per share. | 11 Nov 2021 | 104 | 4,033 (0%) | 0% | 259.5 | 26,985 | ReMed Common Stock |
| Kaushik Ghoshal | President, SaaS Business | Payment of exercise price or tax liability using portion of securities received from the company at price $ 259.47 per share. | 11 Nov 2021 | 976 | 6,424 (0%) | 0% | 259.5 | 253,243 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 10 Nov 2021 | 2,500 | 87,333 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2021 | 2,500 | 22,500 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 260.58 per share. | 10 Nov 2021 | 2,500 | 84,833 (0%) | 0% | 260.6 | 651,450 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 264.29 per share. | 03 Nov 2021 | 1,485 | 120,987 (0%) | 0% | 264.3 | 392,471 | ResMed Common Stock |
| James R. Hollingshead | President, Sleep Business | Sale of securities on an exchange or to another person at price $ 264.35 per share. | 01 Nov 2021 | 2,400 | 73,177 (0%) | 0% | 264.3 | 634,430 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 8,000 | 102,098 | - | - | ResMed Common Stock Options | |
| Robert Andrew Douglas | President and COO ResMed Inc. | Sale of securities on an exchange or to another person at price $ 255.77 per share. | 15 Oct 2021 | 8,000 | 22,149 (0%) | 0% | 255.8 | 2,046,160 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 15 Oct 2021 | 8,000 | 30,149 (0%) | 0% | 58.2 | 465,920 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 253.37 per share. | 11 Oct 2021 | 5,000 | 84,786 (0%) | 0% | 253.4 | 1,266,850 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 11 Oct 2021 | 2,500 | 89,786 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2021 | 2,500 | 25,000 | - | - | ResMed Common Stock Options | |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 260.79 per share. | 04 Oct 2021 | 1,487 | 122,472 (0%) | 0% | 260.8 | 387,795 | ResMed Common Stock |
| James R. Hollingshead | President, Sleep Business | Sale of securities on an exchange or to another person at price $ 261.33 per share. | 01 Oct 2021 | 2,400 | 74,479 (0%) | 0% | 261.3 | 627,183 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.24 per share. | 15 Sep 2021 | 8,000 | 30,149 (0%) | 0% | 58.2 | 465,920 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Sale of securities on an exchange or to another person at price $ 291.83 per share. | 15 Sep 2021 | 8,000 | 22,149 (0%) | 0% | 291.8 | 2,334,640 | ResMed Common Stock |
| Robert Andrew Douglas | President and COO ResMed Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2021 | 8,000 | 110,098 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 2,500 | 27,500 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 297.33 per share. | 10 Sep 2021 | 5,000 | 87,286 (0%) | 0% | 297.3 | 1,486,650 | ResMed Common Stock |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 10 Sep 2021 | 2,500 | 92,286 (0%) | 0% | 57.8 | 144,400 | ResMed Common Stock |
| David B. Pendarvis | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 292.16 per share. | 03 Sep 2021 | 1,487 | 123,959 (0%) | 0% | 292.2 | 434,442 | ResMed Common Stock |
| James R. Hollingshead | President, Sleep Business | Sale of securities on an exchange or to another person at price $ 287.30 per share. | 01 Sep 2021 | 2,400 | 76,879 (0%) | 0% | 287.3 | 689,527 | ResMed Common Stock |
| Rajwant Sodhi | President, SaaS Business | Sale of securities on an exchange or to another person at price $ 288.41 per share. | 01 Sep 2021 | 1,500 | 26,731 (0%) | 0% | 288.4 | 432,615 | ResMed Common Stock |
| Carol J. Burt | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Aug 2021 | 347 | 14,595 (0%) | 0% | 0 | ResMed Common Stock | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 5,543 | 30,000 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 5,193 | 35,543 | - | - | ResMed Common Stock Options | |
| Brett A. Sandercock | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 281.73 per share. | 20 Aug 2021 | 10,736 | 89,786 (0%) | 0% | 281.7 | 3,024,653 | ResMed Common Stock |